Conditions used for HPLC/MS/MS analysis for each drug
Column consisted of either a Phenomenex 2.0 × 30 mm, 5-μm Gemini 110A (column 1) or a Phenomenex 2.0 × 30 mm, 4-μm Synergi Max-RP column (column 2). Mobile phase A, B, and C consisted of ammonium acetate (pH 6.8; 10 mM), methanol, and acetonitrile, respectively. HPLC gradients with the initial and intermediate gradient conditions, as well as the flow rates listed below, were conducted as described under Materials and Methods. Drugs listed with a flow rate of 750 to 1500 were run on a PE-Sciex API-4000. All the other drugs were run on a PE-Sciex API-3000.
Drug | MS Polarity | MRM Transition | Column | Initial Condition | Intermediate Condition | Flow Rate | Internal Standard |
|---|---|---|---|---|---|---|---|
| μl/min | |||||||
| Alfentanil | + | 417.3/268.3 | 1 | 95% A/5% B; 30 s | 10% A/90%B | 750-1500 | Loperamide |
| Amprenavir | + | 506.4/245.4 | 2 | 80% A/20% B | 5% A/95% B | 750-1500 | Ritonavir |
| Cetirizine | + | 389.1/201.1 | 2 | 95% A/5% B | 5% A/95% B | 750-1500 | Fexofenadine |
| Cimetidine | + | 253.1/159.3 | 1 | 95% A/5% B; 30 s | 10% A/90%B | 750-1500 | Fexofenadine |
| Desloratadine | + | 311.0/259.3 | 2 | 95% A/5% B | 5% A/95% B | 750-1500 | Fexofenadine |
| Dexamethasone | - | 391.2/307.3 | 2 | 90% A/5% B/5% C | 5% A/47.5% B/47.5% C | 500-750 | Doxorubicin |
| Digoxin | - | 779.5/649.5 | 2 | 85% A/15% B | 5% A/95% B | 500-750 | Ivermectin |
| Diphenhydramine | + | 256.1/167.3 | 2 | 95% A/5% B | 5% A: /5% B | 750-1500 | Fexofenadine |
| Doxorubicin | - | 542.2/395.5 | 2 | 90% A/5% B/5% C | 5% A/47.5% B/47.5% C | 500-750 | Dexamethasone |
| Eletriptan | + | 383.3/84.6 | 1 | 95% A/5% B; 30 s | 10% A/90%B | 750-1500 | Rizatriptan |
| Fentanyl | + | 337.2/188.2 | 2 | 80% A/20% B | 5% A/95% B | 750-1500 | Loperamide |
| Fexofenadine | + | 502.3/466.4 | 2 | 80% A/20% B | 5% A/95% B | 750-1500 | Loperamide |
| Hydroxyzine | + | 375.1/201.1 | 2 | 95% A/5% B | 5% A/95% B | 750-1500 | Fexofenadine |
| Indinavir | + | 614.5/421.5 | 2 | 80% A/20% B | 5% A/95% B | 750-1500 | Ritonavir |
| Ivermectin | - | 873.6/229.3 | 2 | 85% A/15% B | 5% A/95% B | 500-750 | Digoxin |
| Loperamide | + | 477.4/266.0 | 2 | 95% A/5% B | 5% A/95% B | 750-1500 | Methadone |
| Loratadine | + | 383.0/337.1 | 2 | 95% A/5% B | 5% A/95% B | 750-1500 | Fexofenadine |
| Meperidine | + | 248.3/220.3 | 1 | 95% A/5% B | 5% A/95% B | 750-1500 | Loperamide |
| Methadone | + | 310.3/265.1 | 2 | 80% A/20% B | 5% A/95% B | 750-1500 | loperamide |
| Morphine | + | 286.1/201.1 | 1 | 95% A/5% B; 30 s | 20% A/80% B | 750-1500 | Oxycodone (316.0/298.0) |
| Naratriptan | + | 336.1/98.4 | 1 | 95% A/5% B; 30 s | 10% A/90%B | 750-1500 | Zolmitriptan |
| Nelfinavir | + | 568.3/330.4 | 2 | 80% A/20% B | 5% A/95% B | 750-1500 | Saquinavir |
| Paclitaxel | - | 852.3/525.3 | 1 | 95% A/5% B | 5% A/95% B | 750-1500 | Fexofenadine |
| Quinidine | + | 325.2/307.3 | 2 | 85% A/15% B | 5% A/95% B | 500-750 | Olanzapine (325.2/307.3) |
| Ranitidine | + | 315.1/176.2 | 1 | 95% A/5% B; 30 s | 10% A/90%B | 750-1500 | Fexofenadine |
| Ritonavir | + | 721.5/296.4 | 2 | 80% A/20% B | 5% A/95% B | 750-1500 | Saquinavir |
| Rizatriptan | + | 270.3/158.3 | 1 | 95% A/5% B; 30 s | 10% A/90%B | 750-1500 | Zolmitriptan |
| Saquinavir | + | 671.5/570.5 | 2 | 80% A/20% B | 5% A/95% B | 750-1500 | Ritonavir |
| Sufentanil | + | 387.2/238.4 | 1 | 95% A/5% B | 5% A/95% B | 750-1500 | Loperamide |
| Sumatriptan | + | 296.1/58.5 | 1 | 95% A/5% B; 30 s | 10% A/90%B | 750-1500 | Zolmitriptan |
| Triprolidine | + | 279.1/208.3 | 2 | 95% A/5% B | 5% A/95% B | 750-1500 | Fexofenadine |
| Verapamil | + | 455.4/164.9 | 2 | 90% A/5% B/5% C | 5% A/47.5% B/47.5% C | 500-750 | Vinblastine |
| Vinblastine | + | 811.6/224.1 | 2 | 90% A/5% B/5% C | 5% A/47.5% B/47.5% C | 500-750 | Verapamil |
| Zolmitriptan | + | 288.3/58.5 | 1 | 95% A/5% B; 30 s | 10% A/90%B | 750-1500 | Rizatriptan |